Anti-nociceptive and antipyretic activities of CoV-Pla 3 extract: relevance on symptomatic treatment of Covid-19 Disease
Main Article Content
Abstract
Background: There is an urgent need to search for effective remedies against COVID-19 from the rich and extensive flora of Africa.
Objectives: The aim of this study was to evaluate the anti-nociceptive and anti-pyretic activities of the methanol extract of a herbal combination product, Cov-Pla3 in experimental animals.
Methods: Animal models of nociception and hyperthermia including acetic acid-induced contortion, hot-plateinduced nociception, egg albumin-induced paw edema and Brewer's yeast-induce hyperthermia were adopted.
Results: The results revealed that the Cov-Pla3 extract at all the doses used increased the reaction time in a nonsignificant manner (p > 0.05). However, the increase in reaction time at doses of the extract was significant compared to the baseline (p <0.05). The results also showed that Cov-Pla3 extract at the dose of 125 mg/kg at 90 minutes after administration had the highest anti-nociceptive effect of 49.73 % followed by 46.70 % at the dose of 500 mg/kg at same period. It was also shown that the extract significantly reduced acetic acid-contortions at a dose of 500 mg/kg (p < 0.05) with corresponding inhibition of 73 %. The extract at all the doses used significantly decreased paw edema compared to baseline after 180 minutes of administration (p < 0.05). The anti-pyretic test indicated that Cov-Pla3 significantly reduced temperature at 125 mg and 500 mg/kg after 4 hours of administration (p< 0.05). In conclusion, Cov-Pla3 possesses a combination of analgesic, anti-inflammatory and antipyretic activities.
Conclusion: This scientific evidence, in addition to its safety profile from the LD50 of above 5000 mg/kg, justifies its recommendation for clinical trial use in Covid-19 patients with severe symptoms.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Covid-19 Dashboard by the Center for Systemic Science and Engineering (CSSE) at Johns Hopkin's University. Available at
https://coronavirus.jhu.edu/map.html. Accessed 17th July, 2020.
European Center for Disease Prevention and Control (ECDC). Updates on Covid-19. Available at
https://www.ecdc.europa.eu/en/geographi cal - distribution- 2019- n cov- cases. Accessed 22nd August, 2020.
Hui, D.S., Azhar, E.I., Madani, T.A., Ntoumu, F., Kock, R., Dar, O., et al (2020). The continuing 2019-nCov epidemic threat of
novel coronavirus to global health-The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of
Infectious Diseases 91:264-266.
Youfifard, M., Zali, A., Ali, M.K., Neishaboori, A.M., Zarghi, A., Hosseini, M., and Safari, S. (2020). Antiviral therapy in management of covid-19: a systemic review on current evidences. Archives of Academic Emergency Medicine 8(1):e45.
Rismanbaf, A. (2020). Potential treatment for covid-19: a literature review. Archives of Academic Emergency Medicine 8(1):e29.
Wang, Y., Wang, Y., Chen, Y., and Qin, Q. (2020). Unique epidemiological and clinical features of the emerging 2019 novel
coronavirus pneumonia (Covid-19) implicate special control measures. Journal of Medical Virology 92(6):568-576.
Jacob, J.J., and Ramabadran, K. (1978). Enhancement of nociceptive reaction by opiate antagonists in mice. British Journal of
Pharmacology 64:91-98.
Koster, R.M., Anderson, M., and Beer, E.J. (1959). Acetic acid for analgesic screening. Federation Proceedings 18:412-416.
Niemeger, C.J., Verbiugen, F.J., and Janssen, P. A. (1964). Effects of various drugs on carrageenan-induced edema in rat hind paw. Journal of Pharmacy and Pharmacology 16:310-816.
Williamson, E.M., Okpako, D.T., and Evans, F.J. (1996). Pharmacological methods in phytotherapy research: selection,
preparation and pharmacological evaluations of plant materials. John Wiley and Sons, NY, p147.
Carter, R.B. (1991). Differentiating analgesic and non-analgesic drug activities on rat hot plate: effect of behavioral end point. Pain 47:211-220.
Le Bars G., Gozariu, M., and Cadden, S.W. (2001). Animal models of nociception. Pharmacological Reviews 53:597-652.
Di Rosa M., Giroud, J.P., and Willougby, D.A. (1971). Studies of the mediators by carrageenan and turpentine. Journal of
Pathology 104:15-29.
Ndebia, E.J., Kampang, R., and NkehChugang, B.N. (2007). Analgesic and antiinflammatory properties of aqueous extract
from leaves of Solanium torvum. African Journal of Traditional, Complementary and Alternative Medicines 4(2):240-244.
Tharakan, S., Nomoto, K., Mugashita, S., and Ishukawa, K. (2020). Body temperature correlates with mortality in Covid-19
patients. Critical Care 24(1):298.
Drewry, A.M., Hotchkiss, R., and Kulstad, E. (2020). Response to Body temperature correlates with mortality in covid-19. Critical care 24:460.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 394:497-506.
Manjili, R.H., Zarei, M., Habibi, M., and Manjili, M.H. (2020). Covid-19 as an acute inflammatory disease. Journal of Immunology 205(1):12-19.
Costa de Lucena, T.M., Santos, A.F., Lima, B.R., Borborema, M.E., and Silva, J.A. (2020). Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes and metabolic syndrome. Clinical Research and Reviews 14:597-600.